SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Cameron, H.A.
Right arrow Articles by Ramsay, L.E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cameron, H.A.
Right arrow Articles by Ramsay, L.E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Placebo-Controlled Trial of Ketanserin in the Treatment of Intermittent Claudication

H.A. Cameron

University Department of Therapeutics, Royal Hallamshire Hospital, Sheffield, England

P.C. Waller

University Department of Therapeutics, Royal Hallamshire Hospital, Sheffield, England

L.E. Ramsay

University Department of Therapeutics, Royal Hallamshire Hospital, Sheffield, England

The effect of ketanserin on the symptoms of 21 patients with stable intermittent claudication was examined in a double-blind, placebo-controlled, parallel-group study. Benefit was assessed by repeated treadmill exercise tests, recording claudication and total walking times. After three months' treatment with ketanserin (mean dose 167 mg/day) there was no significant change in claudication time (mean change +12%, 95% CI -9; +33%) or total walking time (mean change -14%, 95% CI - 47%; + 19%). The confidence intervals show that ketanserin treatment is unlikely to be associated with clinically important improvement.

Angiology, Vol. 38, No. 7, 549-555 (1987)
DOI: 10.1177/000331978703800708
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Vasc MedHome page
S. M Dean
Pharmacologic treatment for intermittent claudication
Vascular Medicine, November 1, 2002; 7(4): 301 - 309.
[Abstract] [PDF]


Advertisement